Hansa Biopharma reported positive results from a pivotal Phase III trial of imlifidase, an antibody-cleaving enzyme that enables highly sensitized kidney patients to receive transplants. The trial showed significantly improved kidney function at 12 months compared to controls. This promising data clears a regulatory path with plans for a biologics license application filing by year-end. Imlifidase represents an important advancement for broadening transplant options among patients with advanced kidney disease on dialysis.